Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...
BioSpace15d
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight
DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...
petproductmarketing.co.uk12d
Boehringer Ingelheim Introduce FRONTPRO® Chewable Tablets
Boehringer Ingelheim, the makers of FRONTLINE ®, have introduced FRONTPRO as an innovative expansion of the FRONTLINE product family. FRONTPRO is currently available through e-retailers including Pet ...
pharmaphorum2d
Boehringer says R&D pipeline is the best in its long history
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
Global Bovine Tuberculosis Diagnosis Market Increasing Size, Demand, Growth Rate, And Forecast 2033 - Emergen Research
VANCOUVER, BRITISH COLUMBIA, CANADA, January 19, 2025 /EINPresswire / -- The Bovine Tuberculosis (TB) Diagnosis market is expected to grow from USD 781.5 million in 2024 to USD 1.16 billion by 2033, ...
pharmaphorum3d
Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...